fbpx

DeepIntent Receives Patent for Technology that Enables Marketers to Reach Precise Patient Populations in a HIPAA-Compliant, Privacy-Safe Manner

DeepIntent’s Patient Modeled Audiences Solution Uses Industry’s Most Comprehensive Real-World Clinical Datasets to Precisely Reach Patient Populations, Including Those Facing Rare Diseases and Low Prevalence Conditions

NEW YORK, Jan. 11, 2022 — DeepIntent, the leading healthcare advertising technology company built to influence patient health and business outcomes, today announced that the United States Patent and Trademark Office has granted the company a patent for its Patient Modeled Audiences technology that enables pharmaceutical advertisers to reach highly-qualified patient audiences with speed and precision, in a privacy-safe way.

With the patented Patient Modeled Audiences technology, advertisers can use the industry’s most comprehensive real-world clinical datasets to increase audience quality and improve programmatic campaign performance. The patent positions DeepIntent as the only demand side platform (DSP) that can use the HIPAA-compliant Patient Modeled Audiences technology to determine the correlation between demographics and disease to create precise, campaign-specific modeled audiences.

“Healthcare marketers seeking to raise awareness of new clinical trials and treatments among patients, especially those suffering from rare diseases, have had to cast a wide net to reach clinically-relevant audiences because they didn’t have a solution that offered the necessary scale and precision in a privacy-safe way. The inefficiencies of many existing solutions has led to wasted ad dollars and missed opportunities to improve patient health,” said DeepIntent Founder and CEO Chris Paquette. “Patient Modeled Audiences is a game-changing technology that unlocks the value of real-world healthcare data to improve the audience quality of programmatic campaigns. It represents a huge step forward in our mission to use data science to help marketers reach patients with information that can improve their quality of life.”

DeepIntent’s patented technology is equally as successful at reaching qualified patient audiences for common conditions such as Chronic Obstructive Pulmonary Disease (COPD) and Plaque Psoriasis as it is for low-incidence and rare conditions with a fraction of the prevalence, such as Multiple Sclerosis and Hereditary Angioedema (HAE). The unique technology empowers marketers to reach rare disease patients during the narrow, critical window soon after diagnosis, increasing the likelihood of getting patients on therapy and on their way to wellness.

Patient Modeled Audiences provides complete transparency with visibility into model inputs, scores, and audience selection. It is also tightly integrated with DeepIntent’s DSP for streamlined, end-to-end programmatic activation, measurement, and optimization across all devices and channels, including connected TV.

Reinforcing the company’s growth and momentum, this is the second patent DeepIntent has been granted within six months. The company was recently awarded a patent for its DeepIntent Outcomes™ technology, which optimizes live campaigns based on real-world clinical data to improve audience quality and script performance. Both solutions are a testament to DeepIntent’s mission to improve patient outcomes through the artful use of advertising, data science, and real-world clinical data. In addition, Patient Modeled Audiences was recognized as one of the most innovative products of 2020 by PM360.

To learn more about DeepIntent and its innovative technology that power highly-targeted, HIPAA-compliant patient campaigns, visit www.deepintent.com/marketers/patients/.

About DeepIntent
DeepIntent is leading the healthcare advertising industry with data-driven solutions built for the future. Built purposefully for healthcare marketers, DeepIntent’s platform is proven to drive higher audience quality and script performance. It enables marketers to plan, activate, measure, and optimize their campaigns all within a single platform. Conceived by former Memorial Sloan Kettering data scientists, DeepIntent empowers nine of the top ten pharmaceutical companies and the leading healthcare advertising agencies to improve patient outcomes through the artful use of advertising, data science, and real-world health data. For more information, visit DeepIntent.com or find us on Twitter, Facebook, or LinkedIn.

Press Contact
Finn Partners for DeepIntent
Mena Buscetto
deepintent@finnpartners.com
860-326-1698

More News

Press Release
DeepIntent Outcomes™ Named by PM360 as One of the Most Innovative Products of 2021
NEW YORK, Dec. 13, 2021 — PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries,...
Read More
Press Release
DeepIntent Selected as Exclusive Healthcare DSP for LG Ads Solutions in the U.S.
Effective immediately, DeepIntent will have exclusive rights as the only DSP healthcare advertisers can use to reach LG Ads Solutions’ 20+ million households nationwide...
Read More
Press Release
DeepIntent Survey Reveals That Pharmaceutical Advertising Motivates Patients to Research Treatment and Medication Options
NEW YORK, Oct. 27, 2021 — DeepIntent, the leading independent healthcare marketing technology company built purposefully to influence patient health and business outcomes, today...
Read More